Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
Klotho Neurosciences (NASDAQ: KLTO) was named winner of the 2025 BioTech Breakthrough Award for Cell Therapy Innovation of the Year on November 7, 2025. The company was recognized for its work developing gene and cell therapies using a patented secreted form of the human Klotho gene (s-KL) targeting neurodegenerative and age-related diseases including ALS, Alzheimer’s, and Parkinson’s.
The award highlights Klotho’s focus on therapies that aim to address neuronal aging and deliver durable, disease-modifying benefits.
Klotho Neurosciences (NASDAQ: KLTO) è stata nominata vincitrice del BioTech Breakthrough Award 2025 per Innovazione della Terapia Cellulare dell'Anno il 7 novembre 2025. L'azienda è stata riconosciuta per il suo lavoro nello sviluppo di terapie geniche e cellulari utilizzando una forma secretata brevettata del gene umano Klotho (s-KL) mirata a malattie neurodegenerative e legate all'età tra cui SLA, Alzheimer e Parkinson.
Il premio mette in evidenza l'impegno di Klotho per terapie che mirano a contrastare l'invecchiamento neuronale e a offrire benefici duraturi che modificano la malattia.
Klotho Neurosciences (NASDAQ: KLTO) fue nombrada ganadora del BioTech Breakthrough Award 2025 por Innovación en Terapia Celular del Año el 7 de noviembre de 2025. La empresa fue reconocida por su trabajo en el desarrollo de terapias génicas y celulares utilizando una forma secreta patentada del gen humano Klotho (s-KL) dirigida a enfermedades neurodegenerativas y relacionadas con la edad, incluidas ELA, Alzheimer y Parkinson.
El premio destaca el enfoque de Klotho en terapias que buscan abordar el envejecimiento neuronal y ofrecer beneficios duraderos que modifiquen la enfermedad.
Klotho Neurosciences (NASDAQ: KLTO) 는 2025년 11월 7일 올해의 세포 치료 혁신으로 BioTech Breakthrough Award 2025의 수상자로 선정되었습니다. 이 회사는 ALS, 알츠하이머 및 파킨슨병을 포함한 신경 퇴행 및 연령 관련 질환을 대상으로 인간 Klotho 유전자의 특허된 분비형(s-KL)을 이용한 유전자 및 세포 치료제를 개발한 공로로 인정받았습니다.
이 상은 신경 노화에 대처하고 질병을 지속적으로 변화시키는 이점을 제공하는 치료법에 대한 Klotho의 초점을 강조합니다.
Klotho Neurosciences (NASDAQ: KLTO) a été nommée gagnante du BioTech Breakthrough Award 2025 pour l'Innovation en Thérapie Cellulaire de l'Année le 7 novembre 2025. L'entreprise a été reconnue pour son travail dans le développement de thérapies génétiques et cellulaires utilisant une forme sécrétée brevetée du gène humain Klotho (s-KL) ciblant les maladies neurodégénératives et liées à l'âge, notamment la SLA, la maladie d'Alzheimer et la maladie de Parkinson.
Le prix met en lumière l'accent mis par Klotho sur les thérapies qui visent à contrer le vieillissement neuronal et à apporter des bénéfices durables modifiant la maladie.
Klotho Neurosciences (NASDAQ: KLTO) wurde am 7. November 2025 als Gewinner des BioTech Breakthrough Award 2025 in der Kategorie Innovationen in der Zelltherapie des Jahres ausgezeichnet. Das Unternehmen wurde für seine Arbeit bei der Entwicklung von Gen- und Zelltherapien anerkannt, die eine patentierte sezernierte Form des menschlichen Klotho-Gens (s-KL) verwenden und auf neurodegenerative und altersbedingte Erkrankungen wie ALS, Alzheimer und Parkinson abzielen.
Der Preis hebt Klothos Fokus auf Therapien hervor, die darauf abzielen, neuronale Alterung anzugehen und dauerhafte, krankheitsmodifizierende Vorteile zu liefern.
Klotho Neurosciences (NASDAQ: KLTO) فازت بجائزة BioTech Breakthrough في عام 2025 فئة ابتكار العلاج الخلوي لهذا العام في 7 نوفمبر 2025. تم الاعتراف بالشركة لعملها في تطوير علاجات جينية وخلوية باستخدام شكل مُفرَز حاصل على براءة من جين Klotho البشري (s-KL) المستهدف للأمراض العصبية التنكسية والمرتبطة بالعمر بما في ذلك ALS، والزهايمر، ومرض باركنسون.
تسلط الجائزة الضوء على تركيز Klotho على العلاجات التي تهدف إلى معالجة شيخوخة الخلايا العصبية وتقديم فوائد دائمة تعدل المرض.
- None.
- None.
Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkinson's disease. By targeting the underlying mechanisms of neuronal aging, Klotho's therapies aim to slow, halt, or reverse disease progression, offering durable, disease-modifying benefits for patients with conditions that currently have limited treatment options.
"This award highlights our commitment to translating cutting-edge scientific discoveries into meaningful therapies for patients suffering from neurodegenerative and age-related diseases," said Dr. Joseph Sinkule, Klotho Neurosciences' CEO. "As the global population ages, the need for therapies that address the root causes of age-related conditions has never been greater. Klotho's focus on the human Klotho protein positions us to meet this challenge, developing therapies that not only target neurodegeneration but also have the potential to improve health span and reduce the burden of age-related disease worldwide."
The BioTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global life sciences and biotechnology industries. Conducted annually by BioTech Breakthrough, a leading independent market intelligence organization, the awards celebrate excellence across biopharma, therapeutics, genomics, diagnostics, and research tools.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease.
Investor Contact and Corporate Communications:
Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-wins-the-2025-biotech-breakthrough-cell-therapy-innovation-of-the-year-award-302608758.html
SOURCE Klotho Neurosciences, Inc.
FAQ
What award did Klotho Neurosciences (KLTO) win on November 7, 2025?
Why did KLTO receive the BioTech Breakthrough cell therapy award in 2025?
Which diseases does Klotho Neurosciences target with its s-KL therapies?
Does the 2025 award from BioTech Breakthrough indicate regulatory approval for KLTO therapies?
How might the BioTech Breakthrough award affect investor perception of KLTO stock (NASDAQ: KLTO)?
